Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 2:10:1389.
doi: 10.3389/fimmu.2019.01389. eCollection 2019.

Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering

Affiliations
Review

Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering

Franziska Hübner et al. Front Immunol. .

Abstract

Lichen planus pemphigoides (LPP) is a very rare autoimmune sub-epidermal blistering disease associated with lichenoid skin changes. Initially thought to be a mere variant of more common inflammatory dermatoses, particularly Bullous Pemphigoid (BP) or Lichen Planus (LP), a growing body of evidence suggests that it is a disease entity in its own right. In common with a range of autoimmune blistering diseases, including BP, pemphigoid gestationis (PG), mucous membrane pemphigoid (MMP) and linear IgA dermatosis (LAD), a key feature of the disease is the development of autoantibodies against type XVII collagen (COL17). However, accurately establishing the diagnosis is dependent on a careful correlation between the clinical, histological and immunological features of the disease. Therefore, we present an up to date summary of the epidemiology and etiopathogenesis of LPP, before illustrating the predisposing and precipitating factors implicated in the development of the disease. In addition to a selective literature search, we compare reports of potential drug-induced cases of LPP with pharmacovigilance data available via OpenVigil. We subsequently outline the cardinal clinical features, important differential diagnoses and current treatment options. We conclude by demonstrating that an improved understanding of LPP may not only lead to the development of novel treatment strategies for the disease itself, but may also shed new light on the pathophysiology of more common and treatment-refractory autoimmune blistering diseases.

Keywords: BP180; BP230; Bullous Pemphigoid; Lichen Planus; Lichen planus pemphigoides; autoantibodies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical features of Lichen planus pemphigoides. (A) Violaceous plaques with polygonal configuration affecting the dorsal aspects of the feet, with tense blisters and erosions on non-lesional skin. (B) Close-up view of the right foot. (C) detection of complement factor C3 deposition and, (D) IgG deposition at the dermal-epidermal junction in a punch biopsy from perilesional skin, using direct immunofluorescence microscopy (magnification 200×).

References

    1. Kaposi M. Lichen ruber pemphigoides. Arch Derm Syph. (1882) 24:345–6.
    1. Stingl G, Holubar K. Coexistence of lichen planus and bullous pemphigoid. A immunopathological study. Br J Dermatol. (1975) 93:313–20. 10.1111/j.1365-2133.1975.tb06497.x - DOI - PubMed
    1. Tamada Y, Yokochi K, Nitta Y, Ikeya T, Hara K, Owaribe K. Lichen planus pemphigoides: identification of 180 kd hemidesmosome antigen. J Am Acad Dermatol. (1995) 32:883–7. 10.1016/0190-9622(95)91554-0 - DOI - PubMed
    1. Zillikens D, Caux F, Mascaro JM, Wesselmann U, Schmidt E, Prost C, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol. (1999) 113:117–21. 10.1046/j.1523-1747.1999.00618.x - DOI - PubMed
    1. Matos-Pires E, Campos S, Lencastre A, João A, Mendes-Bastos P. Lichen planus pemphigoides. J Dtsch Dermatol Ges J Ger Soc Dermatol. (2018) 16:335–7. 10.1111/ddg.13434_g - DOI - PubMed

Publication types

MeSH terms